Literature DB >> 19074730

High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.

Jan A Burger1, Maite P Quiroga, Elena Hartmann, Andrea Bürkle, William G Wierda, Michael J Keating, Andreas Rosenwald.   

Abstract

In lymphatic tissues, chronic lymphocytic leukemia (CLL) cells are interspersed with CD68(+) nurselike cells (NLCs), T cells, and other stromal cells that constitute the leukemia microenvironment. However, the mechanism regulating colocalization of CLL and these accessory cells are largely unknown. To dissect the molecular cross talk between CLL and NLCs, we profiled the gene expression of CD19-purified CLL cells before and after coculture with NLCs. NLC coculture induced high-level expression of B-cell maturation antigen and 2 chemoattractants (CCL3, CCL4) by CLL cells. CCL3/CCL4 induction in NLC cocultures correlated with ZAP-70 expression by CLL cells. High CCL3/CCL4 protein levels were found in CLL cocultures with NLCs, and CCL3/CCL4 induction was abrogated by R406, a Syk inhibitor, suggesting that NLCs induce these chemokines via B-cell receptor (BCR) activation. BCR triggering also caused robust CCL3/CCL4 protein secretion by CLL cells. High CCL3 and CCL4 plasma levels in CLL patients suggest that this pathway plays a role in vivo. These studies reveal a novel mechanism of cross talk between CLL cells and their microenvironment, namely, the secretion of 2 T-cell chemokines in response to NLC coculture and BCR stimulation. Through these chemokines, CLL cells can recruit accessory cells and thereby actively create a supportive microenvironment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074730      PMCID: PMC4916945          DOI: 10.1182/blood-2008-07-170415

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  63 in total

Review 1.  BAFF AND APRIL: a tutorial on B cell survival.

Authors:  Fabienne Mackay; Pascal Schneider; Paul Rennert; Jeffrey Browning
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

2.  Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling.

Authors:  Richard J Byers; Ebrahim Sakhinia; Preethi Joseph; Caroline Glennie; Judith A Hoyland; Lia P Menasce; John A Radford; Timothy Illidge
Journal:  Blood       Date:  2008-01-03       Impact factor: 22.113

3.  Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes.

Authors:  M Uguccioni; M D'Apuzzo; M Loetscher; B Dewald; M Baggiolini
Journal:  Eur J Immunol       Date:  1995-01       Impact factor: 5.532

4.  Thymic nurse cells--Ia-bearing epithelium involved in T-lymphocyte differentiation?

Authors:  H Wekerle; U P Ketelsen
Journal:  Nature       Date:  1980-01-24       Impact factor: 49.962

5.  Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22.

Authors:  Paolo Ghia; Giuliana Strola; Luisa Granziero; Massimo Geuna; Giuseppe Guida; Federica Sallusto; Nancy Ruffing; Licia Montagna; Paola Piccoli; Marco Chilosi; Federico Caligaris-Cappio
Journal:  Eur J Immunol       Date:  2002-05       Impact factor: 5.532

6.  Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

Authors:  Meike Burger; Tanja Hartmann; Myriam Krome; Justyna Rawluk; Hirokazu Tamamura; Nobutaka Fujii; Thomas J Kipps; Jan A Burger
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

7.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

Authors:  Pedro Farinha; Hamid Masoudi; Brian F Skinnider; Karey Shumansky; John J Spinelli; Karamjit Gill; Richard Klasa; Nicolas Voss; Joseph M Connors; Randy D Gascoyne
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

8.  Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells.

Authors:  R Krzysiek; E A Lefèvre; W Zou; A Foussat; J Bernard; A Portier; P Galanaud; Y Richard
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

9.  Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia.

Authors:  G Pizzolo; M Chilosi; A Ambrosetti; G Semenzato; L Fiore-Donati; G Perona
Journal:  Blood       Date:  1983-12       Impact factor: 22.113

10.  Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo.

Authors:  N Zamzami; P Marchetti; M Castedo; C Zanin; J L Vayssière; P X Petit; G Kroemer
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  141 in total

Review 1.  [Tumor-associated macrophages: Function and differentiation].

Authors:  G Niedobitek; M H Barros; J H Dreyer; F Hauck; D Al-Sheikhyaqoob
Journal:  Pathologe       Date:  2015-09       Impact factor: 1.011

Review 2.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

3.  CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.

Authors:  Koichi Takahashi; Mariela Sivina; Julia Hoellenriegel; Yasuhiro Oki; Fredrick B Hagemeister; Luis Fayad; Jorge E Romaguera; Nathan Fowler; Michelle A Fanale; Larry W Kwak; Felipe Samaniego; Sattva Neelapu; Lianchun Xiao; Xuelin Huang; Hagop Kantarjian; Michael J Keating; William Wierda; Kai Fu; Wing C Chan; Julie M Vose; Susan O'Brien; Richard E Davis; Jan A Burger
Journal:  Br J Haematol       Date:  2015-09-11       Impact factor: 6.998

Review 4.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

5.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

Authors:  Jan A Burger; Michael J Keating; William G Wierda; Elena Hartmann; Julia Hoellenriegel; Nathalie Y Rosin; Iris de Weerdt; Ghayathri Jeyakumar; Alessandra Ferrajoli; Marylou Cardenas-Turanzas; Susan Lerner; Jeffrey L Jorgensen; Graciela M Nogueras-González; Gracy Zacharian; Xuelin Huang; Hagop Kantarjian; Naveen Garg; Andreas Rosenwald; Susan O'Brien
Journal:  Lancet Oncol       Date:  2014-08-20       Impact factor: 41.316

6.  The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Authors:  Matthew D Blunt; Stefan Koehrer; Rachel C Dobson; Marta Larrayoz; Sarah Wilmore; Alice Hayman; Jack Parnell; Lindsay D Smith; Andrew Davies; Peter W M Johnson; Pamela B Conley; Anjali Pandey; Jonathan C Strefford; Freda K Stevenson; Graham Packham; Francesco Forconi; Greg P Coffey; Jan A Burger; Andrew J Steele
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

7.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

Review 8.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

9.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

10.  Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.

Authors:  Amit K Mittal; Nagendra K Chaturvedi; Karan J Rai; Christine E Gilling-Cutucache; Tara M Nordgren; Margaret Moragues; Runqing Lu; Rene Opavsky; Greg R Bociek; Dennis D Weisenburger; Javeed Iqbal; Shantaram S Joshi
Journal:  Mol Med       Date:  2014-07-15       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.